Dear COMPPARE team, participants, stakeholders and friends, The COMPPARE study has reached an exciting and important phase—thanks to hundreds of prostate cancer patients who chose to participate in this groundbreaking effort. Funded in 2017 by an $11.9 million grant from the Patient-Centered Outcomes Research Institute (PCORI), COMPPARE set out to…
A COMPPARE poster abstract has been accepted by the Patient-centered Outcomes Research Institute (PCORI) and will be presented at its 2024 Annual Meeting, which will take place in Washington, D.C., October 22–23. The two-day event brings together patients, caregivers, researchers and the broader healthcare community to learn about…
Dear COMPPARE team, participants, stakeholders and friends, As you may know, the COMPPARE study was made possible by an initial five-year, $11.9 million grant from the Patient-centered Outcomes Research Institute (PCORI) in 2017 to directly compare the potential benefits and harms of proton therapy to standard radiation therapy when…
Dear COMPPARE team, participants, stakeholders and friends, From the moment enrollment was completed on October 31, 2022 we have turned our focus to retention, and I am pleased to report that retention (keeping patients actively on a study) and data collection rates have been excellent. I am immensely grateful…
Patient Accrual Closes, Participant Surveys are Collected, and Data Analysis Begins In 2017, a research team led by Nancy Mendenhall, M.D., medical director of the UF Health Proton Therapy Institute, was awarded a five-year, $11.9 million grant from the Patient-Centered Outcomes Research Institute (PCORI) to directly compare…
Dear COMPPARE team, participants, stakeholders and friends, I am excited to share with you that on October 31, 2022, COMPPARE closed enrollment with a total of 2,524 participants (1,024 photon patients and 1,500 proton patients; 900 pragmatic, 600 randomized)! This is an exceptional accomplishment given the ongoing national healthcare…
Dear COMPPARE team, participants, stakeholders and friends, I am pleased to announce that on May 3, 2022, UH Seidman Cancer Center enrolled our 2,250th COMPPARE participant! This means we are now 75% of the way through the accrual process, an exceptional accomplishment given the ongoing challenges…
Dear COMPPARE team, participants, stakeholders and friends, I am pleased to announce that on December 14, 2021 Hampton University Proton Therapy Institute enrolled our 2,000th COMPPARE participant! This means we are now two-thirds of the way through with accrual, an exceptional accomplishment given the ongoing challenges presented by COVID-19. …
COMPPARE Principal Investigator Nancy Price Mendenhall, MD, FACR, FASTRO, was invited to speak at the sixth annual Biennial Science of Global Prostate Cancer Disparities in Black Men Conference, held virtually November 10-13, 2021. The Prostate Cancer Transatlantic Consortium launched the event in Jacksonville, FL in 2010. Funded by the National…
Dear COMPPARE team, participants, stakeholders and friends, I am pleased to report that as of August 20 we have enrolled 1,783 prostate cancer patients in COMPPARE, while striving to reach our accrual goal of 900 Pragmatic Proton patients by the end of August. We are working hard to achieve these…
